<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001062.v2.p2" parentStudy="phs001062.v2.p2" createDate="2017-07-28" modDate="2017-08-07">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Patrick Ellinor, MD, PhD</td><td>Massachusetts General Hospital, Boston, MA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Steven Lubitz, MD</td><td>Massachusetts General Hospital, Boston, MA, USA</td></tr>
		<tr><td>Funding Source</td><td>R01HL092577</td><td>National Heart Lung and Blood Institute, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>R01HL092577S1</td><td>National Heart Lung and Blood Institute, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>R21DA027021</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NHLBI TOPMed: MGH Atrial Fibrillation Study</StudyNameEntrez>
	<StudyNameReportPage>NHLBI TOPMed: Massachusetts General Hospital (MGH) Atrial Fibrillation Study</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Massachusetts General Hospital (MGH) Atrial Fibrillation Study was initiated in 2001. The study has enrolled serial probands, unaffected and affected family members with atrial fibrillation. At enrollment participants undergo a structured interview to systematically capture their past medical history, AF treatments, and family history. An electrocardiogram is performed; the results of an echocardiogram are obtained; and blood samples are obtained.</p> <p>For the TOPMed WGS project only early-onset atrial fibrillation cases were sequenced. Early-onset atrial fibrillation was defined as an age of onset prior to 66 years of age.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Probands were included if they had a history of atrial fibrillation. In participants with an extensive family history of atrial fibrillation, additional affected and unaffected family members were enrolled.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="20173747"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22544366"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25124494"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24486271"/>
		</Publication>
		<Publication>
			<Pubmed pmid="16133178"/>
		</Publication>
		<Publication>
			<Pubmed pmid="15629379"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Atrial Fibrillation"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Patrick Ellinor, MD, PhD</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Steven Lubitz, MD</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01HL092577</AttName>
			<Institution>National Heart Lung and Blood Institute, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01HL092577S1</AttName>
			<Institution>National Heart Lung and Blood Institute, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R21DA027021</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01HL104156</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>K24HL105780</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01HL65962</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>K23HL071632</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>K23HL114724</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>13EIA14220013</AttName>
			<Institution>American Heart Association, National Center, Dallas, TX, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>14CVD01</AttName>
			<Institution>Fondation Leducq, Paris, France</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-IRB" longName="Health/Medical/Biomedical (IRB)"/>
		<ConsentGroup groupNum="2" shortName="DS-AF-IRB-RD" longName="Disease-Specific (Atrial Fibrillation, IRB, RD)"/>
	</ConsentGroups>
</Configuration>

  <Documents>
    <Document phd="phd006969.2" type="protocol" createDate="2017-04-03" modDate="2017-08-01" urlToXml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/GetDocumentXml.cgi?document_id=phd006969.2" urlToHtml="http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/document.cgi?study_id=phs001062.v2.p2&amp;phd=6969">
      <OrigName>TOPMed_for_dbGaP_April2016_v5_final.docx</OrigName>
      <DisplayName>TOPMed Whole Genome Sequencing Project</DisplayName>
      <Description>TOPMed Whole Genome Sequencing Project</Description>
      <displayStatus>public</displayStatus>
      <xmlStatus>public</xmlStatus>
    </Document>
  </Documents>



</Study>

</Studies>

</GaPExchange>
